SELLAS Life Sciences Group, Inc.

NasdaqCM SLS

SELLAS Life Sciences Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024

SELLAS Life Sciences Group, Inc. Debt to Equity Ratio is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

SELLAS Life Sciences Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.03.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: SLS

SELLAS Life Sciences Group, Inc.

CEO	Dr. Angelos M. Stergiou M.D., ScD h.c.
IPO Date	March 12, 2008
Location	United States
Headquarters	Times Square Tower
Employees	16
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Key trends

Past 5 years